Myotoxin-Neutralizing Polypeptides for Snakebite Envenomation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antivenom production for snakebite envenomation is limited by adverse reactions, inefficiency in neutralizing local pathological effects, batch-to-batch variation, and reliance on animal-derived antibodies, which are not specifically targeted and have pharmacokinetic limitations.
Innovation Solution
Development of non-natural, myotoxin-neutralizing polypeptides derived from phage display libraries, which can be administered as single active pharmaceutical ingredients, offering targeted and stable treatment options with reduced adverse effects and batch variation, suitable for first-aid use in the field.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal-derived antivenoms are used, then neutralization of venom toxins is achieved, but adverse reactions occur in recipients
Solution Approach 1:
The patent creates synthetic polypeptides that copy the neutralizing function of natural antivenom antibodies without using animal-derived materials. These engineered polypeptides mimic the binding capability of antibodies to neutralize myotoxins while eliminating the immunogenicity and batch variation problems of animal-derived antivenoms
Solution Approach 2:
The patent modifies the chemical and physical parameters of the neutralizing agents by using synthetic polypeptides with controlled amino acid sequences, molecular weights, and structural properties. This allows optimization of neutralization efficacy while reducing adverse reactions through precise control of pharmacokinetic and immunogenicity parameters
2Reliability
If animal immunization procedures are used for antivenom production, then antivenom antibodies are generated, but batch-to-batch variation occurs
Solution Approach 1:
The patent replaces the biological copying process of animal immunization with synthetic copying of specific polypeptide sequences. By designing and synthesizing polypeptides with defined amino acid sequences that specifically bind to myotoxins, the invention eliminates the variability inherent in animal-based production while maintaining reliable neutralization capability
Solution Approach 2:
The patent substitutes the complex biological system of animal immunization with a controlled chemical synthesis process. This replacement of biological variability with chemical precision eliminates batch-to-batch variation while maintaining the essential function of venom neutralization
3Reliability
If traditional antivenom production is used, then venom neutralization is achieved, but production scalability is limited
Solution Approach 1:
The patent uses synthetic polypeptide copying rather than animal-based production, enabling scalable manufacturing through chemical synthesis or recombinant expression systems. This approach can be produced in controlled environments with consistent quality, overcoming the scalability limitations of animal immunization procedures
Solution Approach 2:
The patent optimizes production parameters by using synthetic biology approaches that allow controlled expression of polypeptides in microbial or mammalian cell systems. This enables scalable production with consistent pharmacokinetic properties and reduced batch variation, addressing the productivity limitations of traditional methods
4Reliability
If non-specific antibodies are administered, then venom neutralization occurs, but treatment efficiency is reduced due to irrelevant antibodies
Solution Approach 1:
The patent applies local quality by designing polypeptides with specific structural features and amino acid sequences that are tailored to bind particular myotoxin epitopes. This targeted design ensures that each polypeptide molecule contributes to neutralization without including irrelevant components, improving treatment efficiency
Solution Approach 2:
The patent creates customized copies of antibody binding regions that specifically recognize and neutralize myotoxins. By copying only the essential neutralizing domains with high specificity, the invention eliminates the presence of irrelevant antibodies while maintaining effective venom neutralization
Data Source
AI summary
The present invention relates to polypeptides having myotoxin-neutralizing properties and their use for treatment of envenomation. The present invention further relates to methods for neutralizing a venom using the polypeptide of the invention as well as to methods of treatment of envenomation by administering said polypeptide to a subject in need thereof.